US Patent

US8633194 — Pharmaceutical composition of piperazine derivatives

Formulation · Assigned to UCB SA · Expires 2027-10-16 · 1y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a liquid composition containing a substituted benzhydryl piperazine active substance with reduced amounts of preservatives.

USPTO Abstract

The present invention relates to a liquid composition containing an active substance belonging to the family of substituted benzhydryl piperazines with reduced amounts of preservatives.

Drugs covered by this patent

levocetirizine-dihydrochloride (LEVOCETIRIZINE DIHYDROCHLORIDE)

Patent Metadata

Patent number: US8633194
Jurisdiction: US
Classification: Formulation
Expires: 2027-10-16
Drug substance claim: No
Drug product claim: Yes
Assignee: UCB SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.